ArticleScientific reports2025
Risk factors and predictive modeling in a US population with sarcopenia: a propensity score cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Comprehensive profiling of chemokine and NETosis-associated genes in sarcopenia: construction of a machine learning-based diagnostic nomogram.Frontiers in medicine · 2025Article
- U-Shaped Relationship Between Serum Lactate Dehydrogenase With Diabetic Lower Extremity Ulcers Among Diabetic Patients Aged ≥ 40 Years in NHANES.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sarcopenia, characterized by loss of muscle mass and strength, particularly affects older adults and is linked to increased morbidity and mortality. The study aimed to investigate the relationship between biomarkers, including hemoglobin (Hb), lactate dehydrogenase (LDH), and Systemic Immune-Inflammation Index (SII), and sarcopenia in the US population. Utilizing NHANES data from 2003 to 2018, the study analyzed 5,615 participants, categorizing them based on quartiles of Hb, SII, and LDH levels. It employed logistic regression models to assess the relationship between these biomarkers and sarcopenia risk, adjusting for various confounders. High levels of LDH, Hb and SII were significantly associated with sarcopenia, with higher risk in the highest quartile. The AUC for all indicators in predicting sarcopenia was 0.925 (sensitivity 0.925; specificity 0.743). The study concludes that elevated Hb, LDH, and SII levels are significant biomarkers associated with sarcopenia, emphasizing the role of inflammation in its development and the potential for these markers in early detection and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.